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OBJECTIVE — To determine whether continuous glucose monitoring (CGM) is effective in
the management of type 1 diabetes when implemented in a manner that more closely approxi-
mates clinical practice.
RESEARCH DESIGN AND METHODS — After completion of a 6-month randomized
controlled trial (RCT) evaluating CGM in children, adolescents, and adults with type 1 diabetes,
CGMwasinitiatedinthetrial’scontrolgroupwithlessintensivetrainingandfollow-upthanwas
includedintheRCT.Subjectshadanoutpatienttrainingsession,twofollow-upphonecalls,and
outpatient visits at 1, 4, 13, and 26 weeks. For subjects with baseline A1C 7.0%, the primary
outcome was change in A1C at 6 months.
RESULTS — CGM use decreased from a median of 7.0 days/week in the ﬁrst month in the
25-year-old group, 6.3 days/week in the 15–24 year olds, and 6.8 days/week in the 8–14 year
olds to 6.5, 3.3, and 3.7 days/week in the 6th month, respectively (P  0.001 for each age-
group).AmongsubjectswithbaselineA1C7.0%,CGMusewasassociatedwithA1Creduction
after 6 months (P  0.02 adjusted for age-group). Severe hypoglycemia decreased from 27.7
events per 100 person-years in the 6-month control phase of the RCT to 15.0 events per 100
person-years in the 6-month follow-up CGM phase (P  0.08).
CONCLUSIONS — Frequent use of CGM in a clinical care setting may improve A1C and
reduce episodes of hypoglycemia. However, sustained frequent use of CGM is less likely in
children and adolescents than in adults.
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M
any patients with type 1 diabetes
treated with intensive insulin reg-
imens are unable to achieve and
maintain recommended A1C targets (1).
Even with the availability of insulin
pumpsandshort-andlong-actinginsulin
analogs, patients with type 1 diabetes are
frequently exposed to both excessive hy-
perglycemia and prolonged, dangerous
hypoglycemia, particularly at night (2,3).
Therecentavailabilityofreal-timecontin-
uous glucose monitoring (CGM) devices
has the potential to help users improve
diabetes control by reducing both hyper-
glycemic and hypoglycemic exposures.
We conducted a 6-month random-
izedtrialofCGMplusconventionalblood
glucose monitoring versus blood glucose
monitoring alone in 322 intensively
treated subjects with type 1 diabetes and
baseline A1C 7.0% and demonstrated a
signiﬁcant reduction in A1C in the adult
subjects (aged 25 years) (4). Although
the pediatric (aged 8–14 years) and
young adult (aged 15–24 years) groups
didnotonaverageshowasigniﬁcantdrop
inA1Clevels,thoseindividualswhoused
CGM at least 6 days a week had a reduc-
tion in A1C similar to the 0.5% mean re-
duction in the adults (5). In a parallel
studyof129subjectswithtype1diabetes
and baseline A1C level 7.0%, CGM was
shown to be effective in reducing bio-
chemical hypoglycemia while maintain-
ing A1C levels in the goal range (6).
Although these studies demonstrate
efﬁcacy of CGM in the controlled envi-
ronmentofarandomizedtrialwithinten-
sive subject monitoring and supervision,
the generalizability of these ﬁndings to
subjects receiving diabetes care in a clin-
ical practice setting, in which clinician
visits may be less frequent and of shorter
duration than can be accomplished in a
more rigorous randomized controlled
trial(RCT),isarguablysomewhatlimited.
Consequently, we included a 6-month
single-arm crossover extension to our
randomized trial, to examine whether the
introduction of CGM in a manner that
morecloselyapproximatesaclinicalprac-
tice, would be associated with improve-
ment in glycemic control. This report
describes the results of the experience of
the original control subjects after 6
months of CGM use initiated by a so-
called “standard care management”
approach.
RESEARCH DESIGN AND
METHODS— The protocol was de-
scribedindetailpreviously(4,6,7).Major
eligibility criteria for the randomized trial
includedage8years,type1diabetesfor
at least 1 year, use of either an insulin
pump or at least three daily insulin injec-
tions, and A1C level 10.0%. Subjects
were randomly assigned to either a CGM
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dard home blood glucose monitoring.
This report includes 214 of the 219
subjects in the randomized trial control
group who initiated CGM use for a
6-month period after completion of the
randomized trial. Four subjects did not
complete the randomized trial, and one
subject decided not to continue after
completing the trial.
During the ﬁrst 6 months of the ran-
domized trial, the control group had six
follow-upvisitswithaphonecallbetween
each visit to mirror the schedule in the
CGM group and received written instruc-
tions on how to use blood glucose meter
data to make real-time insulin dose ad-
justments and on using computer soft-
ware (for those with a home computer) to
retrospectively review the glucose data to
alter future insulin dosing (7,8). After
completion of the 6-month outcome of
the randomized trial, each control group
subject was provided with one of the fol-
lowing CGM devices: the DexCom
SEVEN (DexCom, San Diego, CA), the
MiniMed Paradigm REAL-Time Insulin
Pump and Continuous Glucose Monitor-
ing System (Medtronic MiniMed,
Northridge,CA),ortheFreeStyleNaviga-
tor (Abbott Diabetes Care, Alameda, CA).
The CGM initially was used in a blinded
fashion for 1 week; these data served as a
baseline for evaluating change during fol-
low-up. After completion of the blinded
use, subjects were instructed to use the
device on a daily basis and to verify the
accuracy of glucose measurements with a
home blood glucose meter (provided by
the study) before making management
decisions(aspertheregulatorylabelingof
the devices). Target glucose values were
premeal 70 to 130 mg/dl, peak postmeal
180 mg/dl, and bedtime/overnight
100–150 mg/dl. Instructions for insulin
dosing included determination of pre-
meal bolus doses based on the glucose
level, the carbohydrate content of the up-
Figure 1—CGM use over 6 months according to age-group. Box plots indicating sensor use in each 4-week time period for the 212 subjects who
completed the study (two subjects who did not complete the study are not included) are shown. The top and bottom of the boxes denote the 25th and
75th percentiles, the line represents the median, and the dot represents the mean. The numbers of subjects who did not use CGM during a 4-week
period are indicated below each box plot (these data are included in each box plot).
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cosechange,andguidelinesforcorrecting
glucose levels outside the target range at
other times.
Follow-up visits during the clinical
care CGM phase occurred after 1, 4, 13,
and26weeks,withphonecontacts3days
after CGM initiation and 7 days after the
1-week visit. At each visit, A1C was mea-
sured with a point-of-care device (DCA
2000atsevensites,G7-Tosohattwosites,
and Bio-Rad at one site), and at baseline
and 6 months a central laboratory–
measured A1C level was obtained at the
University of Minnesota using the Tosoh
A1c 2.2 Plus Glycohemoglobin Analyzer
method (9).
Statistical methods
Baseline was considered the visit when
real-time CGM was initiated. The ﬁnal
outcome was 6 months later. From the
downloads of the CGM devices per-
formed at each visit, the amount of CGM
use was determined. CGM was consid-
eredtobeusedonadaywhentherewasat
least one glucose value; on 83% of days
withatleastoneglucosevalue,therewere
at least 12 h of glucose values. Change in
CGM use over the 6-month period was
assessedwitharepeated-measuresregres-
sion model based on rank values trans-
formedtohaveanormaldistribution(van
der Waerden scores). van der Waerden
scores were also used in the analysis of
sensor glucose data because of skewed
distributions.TheassociationofCGMuse
6days/weekduringmonth6withbase-
line factors and with CGM use during the
1st month was assessed in logistic regres-
sion models. Analysis of A1C was limited
to subjects with a value 7.0% at base-
line. Change in A1C from baseline to 6
monthswasevaluatedwithapairedttest.
The association between change in A1C
Table 1—Change in A1C from baseline* to month 6 by amount of CGM use in month 6 in subjects with A1C >7.0% at the time of initiation
of CGM
All










n 154 26 45 23 60
Baseline A1C (%)† 7.8 8.0 7.7 7.8 7.6
Change in A1C from baseline to month 6
Mean change (%) 0.1  0.6 0.2  0.9 0.0  0.6 0.4  0.7 0.2  0.4
Improved 0.5% 49 (32) 8 (31) 8 (18) 13 (57) 20 (33)
Worsened 0.5% 27 (18) 8 (31) 13 (29) 2 (9) 4 (7)
A1C 7.0% 29 (19) 2 (8) 5 (11) 9 (39) 13 (22)
Mean change from 0–6 months in prior RCT 0.0  0.6 0.1  0.5 0.1  0.6 0.0  0.7 0.1  0.5
Age-group 25 years
n 51 4 4 6 37
Baseline A1C (%) 7.6 8.0 7.6 7.5 7.6
Change in A1C from baseline to month 6
Mean change 0.4  0.5 0.1  0.9 0.4  0.7 0.5  0.3 0.4  0.4
Improved 0.5% 23 (45) 1 (25) 2 (50) 4 (67) 16 (43)
Worsened 0.5% 3 (6) 1 (25) 1 (25) 0 1 (3)
A1C 7.0% 15 (29) 0 2 (50) 3 (50) 10 (27)
Mean change from 0–6 months in prior RCT 0.2  0.5 0.4  0.5 0.3  0.6 0.3  0.5 0.1  0.4
Age-group 15–24 years
n 56 11 26 7 12
Baseline A1C (%) 7.9 8.1 7.9 8.1 7.7
Change in A1C from baseline to month 6
Mean change (%) 0.0  0.7 0.4  1.2 0.0  0.5 0.6  0.3 0.0  0.3
Improved 0.5% 14 (25) 4 (36) 4 (15) 5 (71) 1 (8)
Worsened 0.5% 10 (18) 4 (36) 5 (19) 0 1 (8)
A1C 7.0% 6 (11) 0 2 (8) 3 (43) 1 (8)
Mean change from 0–6 months in prior RCT (%) 0.1  0.7 0.1  0.5 0.1  0.6 0.1  0.8 0.2  0.7
Age-group 8–14 years
n 47 11 15 10 11
Baseline A1C (%) 7.8 7.8 7.6 7.9 7.8
Change in A1C from baseline to month 6
Mean change (%) 0.0  0.7 0.1  0.6 0.2  0.6 0.2  0.9 0.0  0.6
Improved 0.5% 12 (26) 3 (27) 2 (13) 4 (40) 3 (27)
Worsened 0.5% 14 (30) 3 (27) 7 (47) 2 (20) 2 (18)
A1C 7.0% 8 (17) 2 (18) 1 (7) 3 (30) 2 (18)
Mean change from 0–6 months in prior RCT (%) 0.2  0.6 0.2  0.4 0.1  0.7 0.2  0.7 0.1  0.5
Data are means, means  SD, or n (%). *Baseline refers to the time of initiation of CGM use (following the 6 months in the RCT as control group). †One subject was
missing a baseline laboratory A1C, and the point-of-care A1C was imputed using a least squares regression model.
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with least squares regression models ad-
justingforbaselineA1C.Theincidenceof
severe hypoglycemia (deﬁned as an event
thatrequiredassistancefromanotherper-
son to administer carbohydrate, gluca-
gon, or other resuscitative actions [10])
during the 6-month randomized trial (as
the control group) versus the incidence
during the subsequent CGM use phase
was compared using a signed-rank test.
The association of severe hypoglycemic
events with baseline A1C was assessed
with a Spearman correlation coefﬁcient.
CGM glucose data during the 6th month
were compared with blinded CGM data
obtained immediately before the initia-
tion of unblinded CGM use using a
signed-ranktest.Changesinglucosevari-
ability from baseline to month 6 were
evaluated with and without adjustment
for mean glucose using a repeated-
measures regression model based on the
rank scores.
Analyses included only subjects com-
pleting the 6-month visit. A1C results are
from the central laboratory unless other-
wise stated.
RESULTS— The 214 subjects in-
cluded 80 who were aged 25 years at
the time of initiation of CGM use, 73 who
were 15–24 years old and 61 who were
8–14 years old; 199 (93%) were Cauca-
sian, 3 (1%) were African American, 5
(2%) were Hispanic, and 7 (3%) were
other races. Mean  SD A1C levels at the
time of initiation of CGM use were 7.4 
0.7% (range 5.8–10.1%), with 156
(73%) 7.0% and 58 (27%) 7.0%. An
insulin pump was being used by 171
(80%), the others being treated with mul-
tiple daily injections of insulin. The study
was completed by 212 (99%) of the 214
subjects.
CGM use
As seen in Fig. 1, CGM use tended to de-
crease over time (P  0.001) in all age-
groups, although less so in the adults. In




month 6 to 6.5, 3.3, and 3.7 days/week,
respectively. In month 6, the percentage
of 25 year olds using CGM at least 6
days per week was signiﬁcantly greater
than the percentages in the two younger
age-groups (64, 19, and 25%, respec-
tively, P  0.001). Four (5%), 15 (21%),
and 12 (20%) subjects in the three age-
groups, respectively, were no longer us-
ing CGM in month 6.
The only factor other than age that
was signiﬁcantly associated with lower
CGM use in month 6 was the occurrence
ofaseverehypoglycemiceventduringthe
preceding 6 months (as the control group
in the randomized trial; P  0.008 ad-
justed for age) (supplementary Table 1,
available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1502/DC1). Of
the 10% of patients who experienced a
severe hypoglycemic event in the previ-
ous 6 months, only 14% used CGM 6
days at the end compared with 40% of
those who did not have a severe hypogly-
cemicevent.CGMuseinmonth6didnot
varywiththebaselineA1Clevel(P0.53
adjusted for age). There was a trend to-
ward CGM use being higher in pump us-
ers than in multiple daily injection users
(41 vs. 23%, P  0.07 adjusted for age).
Sensor use in month 6 was strongly
associated with use in the ﬁrst 4 weeks
(P0.001adjustedforage)(supplemen-
taryTable2,availableinanonlineappen-
dix). Sensor use was 6 days/week in
month 6 in 69 (57%) of 122 subjects who
used the sensor at least 27 of 28 days in
the ﬁrst 4 weeks, in 8 (25%) of the 32
subjectswhousedthesensor24–26days,
andin2(3%)ofthe58subjectswhoused





As shown in Table 1, among the 154 sub-
jectswithbaselineA1C7.0%whocom-
pleted the 6-month visit, change in A1C
from baseline to 6 months varied with
age-group (P  0.002). There was a sig-
niﬁcant decrease in 25 year olds (n 
51, mean  SD change 0.4  0.5%,
P0.001)butnotinthe15–24yearolds
(n  56, 0.01  0.7%, P  0.95) or in
the eight to 14 year olds (n  47,
0.02  0.7%, P  0.85). This associa-
tion of change in A1C and age-group was
related to the amount of CGM use.
Greater CGM use was associated with a
greater A1C decrease (P  0.01 adjusted
for age-group) (Table 1), and after adjust-
ment for CGM use, the relationship be-
tween age-group and change in A1C was
weaker (P  0.07). In subjects with base-
line A1C 7.0%, mean A1C was 6.6% at
baseline and 6.8% at 6 months
Severe hypoglycemia
The incidence rate of severe hypoglyce-
mic events was 15.0 events per 100 per-
son-years during the 6 months of the
follow-up. This rate trended lower than
the rate in these subjects in the 6 months
of the randomized trial that preceded this
Table 2—Rate of severe hypoglycemia 6 months before CGM use and during 6 months of CGM use
Severe hypoglycemia 6-month control period 6-month CGM use period
Age 25 years 38.5 person-years (n  78) 39.1 person-years (n  78)
n events (n seizure or loss of consciousness) 13 (2) 9 (2)
n (%) subjects with at least 1 event 9 (12) 8 (10)
Incidence rate (per 100 person-years) 33.7 23.0
Age 15–24 years 35.9 person-years (n  73) 36.6 person-years (n  72)
n events (n seizure or loss of consciousness) 8 (3) 3 (2)
n (%) subjects with at least 1 event 7 (10) 3 (4)
Incidence rate (per 100 person-years) 22.3 8.2
Age 8–14 years 30.3 person-years (n  61) 30.8 person-years (n  61)
n events (n seizure or loss of consciousness) 8 (1) 4 (2)
n (%) subjects with at least 1 event 6 (10) 3 (5)
Incidence rate (per 100 person-years) 26.4 13.0
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years, P  0.08). A similar trend was
present in all three age-groups as seen in
Table 2. The severe hypoglycemia inci-
dence rate during the 6 months of CGM
use was not signiﬁcantly associated with
baseline A1C (P  0.26).
CGM glucose data
In the 25-year-old group, there was an
increase in time per day with the glucose
level in the range of 71–180 mg/dl, with a
decrease in the time in both the hypogly-
cemic range and hyperglycemic range
(Table 3). In the 15–24 year olds, there
was a decrease in time in the hypoglyce-
micrangebutnoconsistentchangeinhy-
perglycemia. In the 8–14 year olds, there
wasnosubstantialchangeintimespentas
hypoglycemic or hyperglycemic. Results
were similar for both daytime and night-
time (supplementary Table 4, available in
an online appendix) and in subgroups
based on baseline A1C (7.0% and
7.0%) (supplementary Table 5, avail-
able in an online appendix).
CONCLUSIONS— A purpose of this
study was to determine whether CGM is
beneﬁcial for individuals with type 1 dia-
betes when implemented in a manner
typical of a clinical practice setting, as we
hadshowninthemoreintensiveRCTset-
ting. Unlike in the RCT, the subjects in
this study had a full 6 months of intensi-
ﬁcation of treatment and optimization of
metabolic control using standard glucose
monitoring before starting CGM. Never-
theless, in qualitative terms the results
were similar to those that we had previ-
ouslyobservedintheRCT.Adultsubjects
with baseline A1C levels 7.0% had a
signiﬁcantreductioninA1C(0.4%);no
reduction in A1C was seen in the two
younger age-groups. As in the RCT, after
adjustment for frequency of CGM use,
there was no signiﬁcant relationship
between age and change in A1C. Subjects
inthe6-monthextensionstudywhoused
the devices consistently also saw a signif-
icantincreaseintheamountoftimespent
in the target glucose range and decreased
exposure to hyperglycemia. The associa-
tionbetweentheamountofCGMuseand
reduction in A1C also was found in the
GuardControl study, in which a signiﬁ-
cant improvement in A1C levels over 3
months was observed in individuals with
poorly controlled type 1 diabetes who
were assigned to use CGM continuously
compared with a control group but not in
those assigned to use CGM intermittently
(11). An interesting and somewhat coun-
terintuitive ﬁnding was that the occur-
renceofaseverehypoglycemicepisodein
the previous 6 months was a strong pre-
dictor of lack of sensor use at the conclu-
sion of the study. It is possible (but
speculative) that in this context, the
occurrence of severe hypoglycemia and
nonuse of CGM may both be surrogate
markers for difﬁculties with diabetes
management–related tasks and be-
haviors.
Despite less intensive implementa-
tionofCGMinthisstudy,theexposureto
biochemical hypoglycemia was reduced
in all three age-groups, although the dif-
ference did not achieve statistical signiﬁ-
Table 3—Glycemic indices
Age 25 years (n  74)* Age 15–24 years (n  55)* Age 8–14 years (n  44)*
Baseline
(blinded) Month 6 P
Baseline
(blinded) Month 6 P
Baseline
(blinded) Month 6 P
Glucose (mg/dl) 157  25 152  18 0.08 165  27 173  28 0.02 172  29 169  28 0.50
Minimum/day
71–180 mg/dl 882 980 0.001 822 788 0.14 797 812 0.18
Hypoglycemia
Minimum/day (mg/dl)
70 55 45 0.02 93 55 0.005 56 37 0.61
60 20 17 0.006 49 23 0.001 19 11 0.23
50 5 4 0.02 19 4 0.008 2 1 0.61
AUC† 0.3 0.3 0.008 0.7 0.3 0.002 0.4 0.2 0.42
LBGI 0.9 0.9 0.02 1.5 0.9 0.004 1.0 0.8 0.56
Hyperglycemia
Minimum/day (mg/dl)
180 439 390 0.03 494 582 0.03 569 568 0.37
200 296 256 0.004 381 436 0.03 460 452 0.23
250 114 72 0.0001 166 210 0.07 218 193 0.58
AUC‡ 15.1 12.1 0.001 21.7 25.0 0.06 25.3 23.9 0.43
HBGI 6.8 5.8 0.002 8.2 9.4 0.04 9.6 9.6 0.45
Glycemic variability§
SD (mg/dl) 60 54 0.001 (0.001) 67 68 0.35 (0.38) 66 66 0.61 (0.95)
MAGE (mg/dl) 110 100 0.14 (0.35) 126 124 0.44 (0.38) 129 119 0.04 (0.06)
MARC (mg   dl
1  
min
1) 0.65 0.68 0.13 (0.03) 0.79 0.80 0.01 (0.16) 0.75 0.77 0.72 (0.49)
Coefﬁcient of variation
(%) 38 36 0.002 (0.001) 41 41 0.27 (0.32) 41 39 0.99 (0.90)
Data are means  SD and medians unless otherwise indicated. *n includes subjects with at least 24 h of data at both baseline and month 6. †Total area 70 mg/dl,
reﬂectingbothpercentageandseverityofglucosevaluesinthehypoglycemicrange.‡Totalarea180mg/dl,reﬂectingbothpercentageandseverityofglucosevalues
inthehyperglycemicrange.§Forvariability,thePvaluesunadjustedandadjustedformeanglucosearebothgiven:unadjusted(adjusted).Coefﬁcientofvariation
SD/mean. AUC, area under the curve; LBGI, low blood glucose index (13); HBGI, high blood glucose index (13); MAGE, mean amplitude of glycemic excursions;
MARC, mean absolute rate of change.
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determine the rate of severe hypoglyce-
mic events in these subjects with opti-
mized management with standard blood
glucose monitoring (i.e., 27.7 events per
100 patient years). Although the study
was not powered to detect a difference in
severe hypoglycemic events, it is note-
worthy that the rate of severe hypoglyce-
miawasreducedbyalmost50%whenthe
formercontrolsubjectsswitchedtoCGM.
There were some differences in the
response to CGM when it was imple-
mented with a less intensive approach to
follow-upcontacts.Acrossallage-groups,
the frequency of use of CGM was reduced
compared with that in the original CGM
group in the RCT. Less frequent use may
have contributed to the slightly smaller
fall in A1C levels in adults with baseline
A1C values 7.0%. It would not be sur-
prising to learn that the effectiveness of
CGMasanadjuncttostandardbloodglu-
cose monitoring in individuals with type
1 diabetes is enhanced with more fre-
quent personal contact with diabetes cli-
nicians (12). These contacts may have
helped to troubleshoot device-related is-
sues such as alarms, calibrations, and site
irritation that greatly affect the frequency
of home CGM use. As CGM technology
continues to evolve, focus should be
placed on improvements likely to increase
independent use of the devices, such as re-
ductioninsensorsize,lessfrequentneedfor
calibration, greater accuracy resulting in
fewer false alarms, and computer or web-
based training modules to aid in the inter-
pretation and application of sensor data, so
thatthebeneﬁtsofCGMcanbemoreeasily
realized in clinical practice.
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